CytoSorbents Corporation (CTSO)
| Market Cap | 83.20M |
| Revenue (ttm) | 37.73M |
| Net Income (ttm) | -35.56M |
| Shares Out | 43.56M |
| EPS (ttm) | -0.68 |
| PE Ratio | n/a |
| Forward PE | 106.38 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 183,526 |
| Open | 2.00 |
| Previous Close | 1.97 |
| Day's Range | 1.88 - 2.00 |
| 52-Week Range | 1.69 - 9.80 |
| Beta | 0.36 |
| Analysts | Buy |
| Price Target | 8.84 (+362.8%) |
| Earnings Date | Aug 2, 2022 |
About CTSO
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology. Its flagship product is CytoSorb, an extracorporeal cytokine filter for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention and treatment of perioperative complications of cardiopulmonary bypass surgery, and maintaining or enhancing the quality of solid organs harves... [Read more...]
Financial Performance
In 2021, CytoSorbents's revenue was $43.17 million, an increase of 5.27% compared to the previous year's $41.00 million. Losses were -$24.56 million, 213.4% more than in 2020.
Financial StatementsAnalyst Forecast
According to 10 analysts, the average rating for CTSO stock is "Buy." The 12-month stock price forecast is 8.84, which is an increase of 362.83% from the latest price.
News
CytoSorbents (CTSO) Reports Q2 Loss, Lags Revenue Estimates
CytoSorbents (CTSO) delivered earnings and revenue surprises of -78.57% and 11.15%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
CytoSorb® Becomes a Featured Blood Purification Therapy on Fresenius Medical Care Critical Care Platforms
Fresenius Medical Care and CytoSorbents have expanded their partnership via a multi-stage collaboration designed to seize new sales opportunities and jointly develop future innovations CytoSorb will be ...
CytoSorbents Reports Second Quarter 2022 Financial and Operational Results
PRINCETON, N.J. , Aug. 2, 2022 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blo...
CytoSorbents to Report Second Quarter 2022 Operating and Financial Results
PRINCETON, N.J. , July 25, 2022 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blo...
The 2022 CytoSorb World Users' Meeting Highlights the Broad Market Potential of CytoSorb as an Interdisciplinary Ther...
PRINCETON, N.J. and BERLIN , July 8, 2022 /PRNewswire/ -- During the recent 2022 CytoSorb Users' Meeting in Berlin, Germany hosted by CytoSorbents Corporation (NASDAQ: CTSO), leading critical care speci...
Leading Critical Care and Cardiac Surgery Specialists from 40 Countries Meet to Discuss CytoSorb and the New Dimensio...
The 2022 CytoSorb World Users' Meeting focuses on groundbreaking new applications of the adsorption technology to celebrate the 10th anniversary of commercialization PRINCETON, N.J. and BERLIN , July 1,...
3 Stocks Under $3 Insiders Are Aggressively Buying
The Nasdaq Composite dropped by more than 400 points on Friday. Investors, meanwhile, focused on some notable insider trades.
CytoSorbents to Hold 2022 Annual Meeting of Stockholders Virtually
PRINCETON, N.J. , June 2, 2022 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using bloo...
CytoSorbents Partners with Nikkiso to Distribute the PureADJUST Hemoperfusion Blood Pump and Supplies in 14 Countries
Stand-alone Blood Pump Business Model is expected to Enable Expanded Use and Increased Adoption of CytoSorb ® PRINCETON, N.J. , June 1, 2022 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a l...
CytoSorbents to Present at Two Upcoming Investor Conferences
MONMOUTH JUNCTION, N.J. , May 19, 2022 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery us...
CytoSorbents Reports First Quarter 2022 Results and Revises 2022 Outlook
Q1 2022 total revenue was $8.7 million, including product sales of $7.9 million. Core non-COVID-19 product sales were an estimated $7.6 million, and on a constant currency basis were comparable to core...
CytoSorbents Awarded Preferred Supplier Agreement with Asklepios, One of the Largest Private Hospital Operators in Ge...
MONMOUTH JUNCTION, N.J. , May 2, 2022 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery usi...
First Patient Enrolled in U.S. STAR-D Pivotal Trial Evaluating the DrugSorb™-ATR Antithrombotic Removal System to Rem...
MONMOUTH JUNCTION, N.J. , April 29, 2022 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using bl...
CytoSorbents Highlights the Strategy of "Enhanced Lung Rest" Using CytoSorb with ECMO to Help Treat Lung Failure at t...
MONMOUTH JUNCTION, N.J. , April 28, 2022 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery...
CytoSorbents to Report First Quarter 2022 Operating and Financial Results
MONMOUTH JUNCTION, N.J. , April 19, 2022 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surger...
CytoSorbents To Expand Direct Sales of CytoSorb® to the United Kingdom, the Sixth Largest Medical Device Market in th...
MONMOUTH JUNCTION, N.J. , April 14, 2022 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery...
CytoSorbents Receives Approximately $740,000 from the New Jersey Business Tax Certificate Transfer Program
MONMOUTH JUNCTION, N.J. , April 7, 2022 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery ...
CytoSorbents Appoints Jiny Kim, MBA to its Board of Directors
MONMOUTH JUNCTION, N.J. , April 5, 2022 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery...
CytoSorbents Highlights Activities at the Live 41st International Symposium on Intensive Care and Emergency Medicine ...
MONMOUTH JUNCTION, N.J. , March 17, 2022 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surger...
CytoSorbents Reports Fourth Quarter and Full Year 2021 Results and Provides 2022 Outlook
MONMOUTH JUNCTION, N.J., March 8, 2022 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery us...
CytoSorbents to Report Fourth Quarter and Full Year 2021 Operating and Financial Results
MONMOUTH JUNCTION, N.J., Feb. 8, 2022 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery u...
CytoSorbents Announces Participation in Two Upcoming Virtual Investor Conferences
MONMOUTH JUNCTION, N.J., Feb. 3, 2022 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery usi...
First Patient Enrolled in the PROCYSS Multicenter Randomized Controlled Trial Evaluating CytoSorb® to Restore Hemodyn...
MONMOUTH JUNCTION, N.J., Feb. 1, 2022 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery u...
New Publication Reports Significant Reductions in Perioperative Bleeding Complications Following Acute Aortic Dissect...
MONMOUTH JUNCTION, N.J. , Jan. 24, 2022 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery...
CytoSorbents Expects Upside FY21 Sales, Despite COVID-19 Headwinds
CytoSorbents Corp (NASDAQ: CTSO) reported preliminary Q4 FY21 revenue of approximately $10.8 million, better than the consensus of $9.58 million. It reported revenue of $12.0 million in Q4 2020.